Insights·Pharma·November 2026
FDA compliance remediation
Fifteen working days
When FDA finds a problem at a drug or device manufacturer, the response clock starts immediately. Most help arrives after it has already run down.
An FDA inspection that ends with a Form 483 gives the manufacturer a short window to respond, and FDA expects a response to a warning letter within 15 working days. A good response needs a credible plan: root cause, corrective actions, timelines and evidence. Many quality teams do not have the spare capacity to write one while running production.
The timing problem is that enforcement becomes public late. In our tracking, warning letters typically appear on FDA's site about two weeks after they are issued. By the time anyone outside the company can see the letter, a large part of the response window is gone.
That makes the lane about current signal, not lists. A manufacturer that received a 483 last year is having a different conversation from one inspected last month. The useful introduction connects a firm with a fresh observation to a consultancy that has capacity right now and has handled that exact type of finding.
The supply side is mostly small, specialised firms: former FDA investigators and CGMP, validation and quality-systems consultants. They do their best work when the engagement starts early, and they rarely have a reliable way to hear about new enforcement before their competitors do.
- In our tracking, roughly 40 to 50 US drug, device and biologics firms a month receive a 483 or an Official Action Indicated outcome.
- Roughly 15 to 20 warning letters a month go to firms in those categories.
- Recalls reported through openFDA add manufacturers who need corrective action outside the inspection cycle.